Sio Gene Therapies Statistics
Share Statistics
Sio Gene Therapies has 0
shares outstanding. The number of shares has increased by 0%
in one year.
| Shares Outstanding | n/a |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1 |
| FTD / Avg. Volume | n/a |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -0.68 and the forward
PE ratio is null.
Sio Gene Therapies's PEG ratio is
-0.01.
| PE Ratio | -0.68 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 0.81 |
| P/FCF Ratio | -0.8 |
| PEG Ratio | -0.01 |
Financial Ratio HistoryEnterprise Valuation
Sio Gene Therapies has an Enterprise Value (EV) of -12.16M.
| EV / Sales | 0 |
| EV / EBITDA | 0.17 |
| EV / EBIT | 0.2 |
| EV / FCF | 0.2 |
Financial Position
The company has a current ratio of 5.52,
with a Debt / Equity ratio of 0.04.
| Current Ratio | 5.52 |
| Quick Ratio | 5.52 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | -0.04 |
| Debt / FCF | -0.04 |
| Interest Coverage | -2676.56 |
Financial Efficiency
Return on Equity is -119.12% and Return on Invested Capital is -115.37%.
| Return on Equity | -119.12% |
| Return on Assets | -95.75% |
| Return on Invested Capital | -115.37% |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-5,990,583.33 |
| Employee Count | 12 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 259K |
| Effective Tax Rate | -0.36% |
Stock Price Statistics
The stock price has increased by 0.42% in the
last 52 weeks. The beta is 1.08, so Sio Gene Therapies's
price volatility has been higher than the market average.
| Beta | 1.08 |
| 52-Week Price Change | 0.42% |
| 50-Day Moving Average | 0.39 |
| 200-Day Moving Average | 0.39 |
| Relative Strength Index (RSI) | 83.21 |
| Average Volume (20 Days) | 62,408 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -72.27M |
| Net Income | -71.89M |
| EBITDA | -70.94M |
| EBIT | -71.6M |
| Earnings Per Share (EPS) | -0.98 |
Full Income StatementBalance Sheet
The company has 63.73M in cash and 2.52M in
debt, giving a net cash position of 61.21M.
| Cash & Cash Equivalents | 63.73M |
| Total Debt | 2.52M |
| Net Cash | 61.21M |
| Retained Earnings | -862.96M |
| Total Assets | 47.27M |
| Working Capital | 45.12M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -60.35M
and capital expenditures -695K, giving a free cash flow of -61.04M.
| Operating Cash Flow | -60.35M |
| Capital Expenditures | -695K |
| Free Cash Flow | -61.04M |
| FCF Per Share | -0.83 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
